New Drug Combination vs. Standard Hormone Treatment for Early Uterine Cancer in Young Women

Plain-English translation of NCT05247268 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a combination of two medications— (a hormone-regulating injection) plus letrozole (a daily pill)—works better than standard hormone pills alone for treating early-stage uterine cancer in women ages 18 to 45 who want to keep their uterus and fertility. The study will compare how well this medication combination shrinks or eliminates the cancer, and what side effects patients experience.

Young women diagnosed with early uterine cancer face a difficult choice: standard treatment usually requires removing the uterus, which ends their ability to have biological children. This trial is testing whether the new medication combination can effectively treat the cancer while allowing women to keep their uterus and preserve their fertility.

Do you qualify?

You likely qualify if…

you are between 18 and 45 years old
you have been newly diagnosed with early-stage, low-grade uterine cancer (endometrioid type, grade 1) without spread into the muscle layer or beyond the uterus
you have imaging tests (MRI, CT scan, or ultrasound) showing no deep invasion or spread outside the uterus
you strongly want to preserve your ability to have children and keep your uterus
you are able and willing to attend follow-up visits every 3 months at the hospital

You likely don't qualify if…

you have cancer that has invaded the uterine muscle layer or spread outside the uterus
you have had uterine cancer before
you have serious liver or kidney disease or other severe medical conditions
you have breast cancer or other hormone-sensitive cancers
you are currently pregnant or unable to avoid pregnancy during the trial

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication combination or the standard hormone treatment. One group will receive injections every 4 weeks plus daily pills; the other group will take daily hormone pills. Every 3 months, you will have a brief procedure (hysteroscopy) where doctors look inside your uterus with a thin camera to check how the cancer is responding. Treatment may last up to 6 months, with ongoing monitoring to assess your cancer response, side effects, and whether your fertility is preserved.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

Obstetrics and Gynecology Hospital, Fudan University, Shanghai